Ceftibuten/Ledaborbactam Etzadroxil

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameCeftibuten/Ledaborbactam Etzadroxil
Drug Alias NameBL/VNRX-7145Ceftibuten/VNRX-7145
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionBacterial penicillin-binding protein inhibitorsCell wall inhibitorsBeta Lactamase inhibitors
TargetsBeta LactamaseBacterial penicillin-binding protein
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsCardiomyopathy, DilatedBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Ceftibuten DihydrateLedaborbactam Etzadroxil
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesVenatorx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBasilea Pharmaceutica LtdBasilea PharmaceuticaVenatorx Pharmaceuticals Inc +[4] 
Inactive CompaniesN/A
Active IndicationsDrug-Related Side Effects and Adverse ReactionsCardiomyopathy, DilatedBacterial Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A